Technical Information:

Accuracy: The accuracy of the Ascensia CONTOUR Blood Glucose Monitoring System has been assessed in a corre- lation study conducted by healthcare professionals. In this study, 108 fresh capillary blood specimens were tested with the Ascensia CONTOUR Blood Glucose Monitoring System by 108 untrained people with diabetes using three test strip lots. The reference measurement was done on the YSI Glucose Analyzer. Ascensia CONTOUR data compare well with the results from the YSI method.

Regression Statistics (Plasma/Serum Reference): plasma reference glucose range: 75 to 397 mg/dL

Lot

y =

Correlation

Coefficient (r)

 

 

 

 

 

1

1.02x – 0.12 mg/dL

0.972

 

 

 

2

1.03x – 4.34 mg/dL

0.963

 

 

 

3

0.95x – 0.41 mg/dL

0.974

 

 

 

Precision: A study was conducted with the Ascensia CONTOUR Blood Glucose Monitoring System with five heparinized whole blood specimens with glucose levels from 40 to 325 mg/dL. Multiple replicates (n=100) were tested using multiple Ascensia CONTOUR Blood Glucose Meters and one lot of Ascensia CONTOUR Blood Glucose Test Strips. The following precision results were obtained:

Plasma/Serum:

Mean

 

SD

Coefficient

 

of variation

 

 

 

 

 

 

 

38 mg/dL

 

1.9 mg/dL

4.8%

 

 

 

 

101 mg/dL

 

5.1 mg/dL

5.1%

 

 

 

 

118 mg/dL

 

4.4 mg/dL

3.7%

 

 

 

 

205 mg/dL

 

6.8 mg/dL

3.3%

 

 

 

 

326 mg/dL

 

11.7 mg/dL

3.6%

 

 

 

 

 

www.BayerDiabetes.com

35

Technical Information

Extras

Page 37
Image 37
Bayer HealthCare CONTOUR Blood Glucose Meter and Ascensia CONTOURTM Test Strips manual Technical Information

CONTOUR Blood Glucose Meter and Ascensia CONTOURTM Test Strips specifications

The Bayer HealthCare CONTOUR Blood Glucose Meter, alongside Ascensia CONTOURTM Test Strips, represents a significant advancement in diabetes management technology. Designed for both ease of use and accuracy, this glucose monitoring system is tailored to meet the needs of individuals living with diabetes.

One of the main features of the CONTOUR Blood Glucose Meter is its simplicity. The device has a user-friendly interface that guides users through the testing process. With a large, easy-to-read display, results are presented clearly, enabling quick interpretation. The meter is compact and lightweight, making it convenient for on-the-go testing.

An important technological advancement in the CONTOUR Blood Glucose Meter is its advanced multi-pulse technology. This feature allows for more accurate readings by taking multiple measurements during a single test. This ensures that fluctuations in blood glucose levels are captured more effectively, delivering a precise result that the user can rely on.

The Ascensia CONTOURTM Test Strips work in tandem with the meter, utilizing a unique "No Coding" technology. This eliminates the need for coding the strips, reducing the chances of user error. The test strips are designed to require only a small blood sample, which simplifies the testing process and minimizes discomfort. Additionally, they employ a state-of-the-art biosensor technology that enhances the speed and accuracy of the readings.

Another characteristic of the CONTOUR Blood Glucose Meter is its storage capacity for test results. Users can store a significant number of previous readings, which is invaluable for tracking trends over time. This feature assists with self-management, allowing users and their healthcare professionals to make well-informed decisions based on historical data.

Furthermore, the CONTOUR system is designed to provide users with visual cues, such as color-coded ranges that indicate whether readings are within a target range. This aids in better understanding and managing blood glucose levels.

In conclusion, the Bayer HealthCare CONTOUR Blood Glucose Meter and Ascensia CONTOURTM Test Strips stand out in diabetes care with their innovative technology and user-oriented design. These features not only enhance accuracy but also empower users in their journey of managing diabetes, demonstrating a commitment to improving health outcomes.